PosterSessionOnline

INTERNATIONAL LIVER CANCER ASSOCIATION

ILCA 2026 Annual Conference

3-5 September 2026, Brussels

N. Poster

Poster title

Applicant name

Status


P-01	An Immune-Related Pathologic Response Score Predicts Survival After Immune Checkpoint Inhibitor–Based Conversion Therapy in Hepatocellular Carcinoma	Yijun Lu	Received

P-02	Molecular profiling of hepatocellular nodules in vascular liver diseases refines nosological classification and reveals a distinct genomic landscape	Sabrina Sidali	Received

P-03	ST-single cell composition of tertiary lymphoid structures and prediction of response to immunotherapy in HCC	Dylan James Crawshaw	Received

P-05	NSUN2-mediated RNA m5C metabolic reprogramming drives NK-cell immune evasion in hepatocellular carcinoma	Shengwei Mao	Received

P-06	miRNAs as biomarkers of platinum resistance in patients with advanced biliary tract cancer undergoing second-line FOLFOX: a translational analysis of the ABC-06 trial.	Giulia Tesini	Received

P-07	Cirrhotic MASLD-HCC is associated with a distinct immunosuppressive tumor microenvironment and poorer outcomes in atezolizumab plus bevacizumab treatment as opposed to non-cirrhotic counterparts	Guillem Cano Segarra	Received

P-08	Transcriptome-wide identification of immunogenic tumoral antigens in advanced hepatocellular carcinoma reveals non-canonical targets for novel immunotherapy strategies	Frederik Peeters	Received

P-09	Dual Role of ATR in Metabolic Homeostasis and Malignant Transformation in MASLD	QIYUAN HE	Received

P-11	Prognostic Implications and Risk Stratification of Bleeding Events in Advanced Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab	Fujimasa Tada	Received

P-12	Lenvatinib plus Hepatic-Arterial Infusion Chemotherapy with Cisplatin for Patients with Advanced Hepatocellular Carcinoma Refractory to or Unsuitable for Immune-Checkpoint Inhibitors: A Multicenter, Randomized, Phase II Trial in Japan	Norikazu Tanabe	Received

P-14	Serum Osteoprotegerin Predicts Hepatocelluar carcinoa in Metabolic Dysfunction-associated Steatotic Liver Disease	Dae Won Jun	Received

P-15	Impact of Changes in Smoking Status on Hepatocellular Carcinoma Risk in Patients with MASLD: A Nationwide Cohort Study	Dae Won Jun	Received

P-17	Integration of postoperative ctDNA methylation and microvascular invasion for minimal residual disease detection and early recurrence prediction in hepatocellular carcinoma	Senquan Zhang	Received

P-18	Spatial multi-omics reveals an immunotherapy-induced drug-tolerant persister state in hepatocellular carcinoma	Xinrong Yang	Received

P-19	Circulating neoantigen-specific T cells predict immunotherapy response, monitor resistance, and reveal a stress-associated targetable state	Muzi Cao	Received

P-20	Gut microbial composition contributes to the risk of early recurrence after neoadjuvant immunotherapy in resectable hepatocellular carcinoma	Sarah Cappuyns	Received

P-21	Senescence defines distinct metabolic-immune states and an altered immune microenvironment in hepatocellular carcinoma	Marie Jennifer Dorosan	Received

P-22	Integrated molecular and histological profiling of liver yolk sac tumor and its patient-derived cell line reveals c-MYC–FOXM1 oncogenic dependencies	Merle Fischer	Received

P-24	Hyperoxic stress in the circulation reprograms circulating tumor cells toward dormancy and metastatic fitness in hepatocellular carcinoma	Xin-rong Yang	Received

P-26	Fate determination of progenitor exhausted-like CD8+ T cells in the tumor/draining lymph node immune axis and its role in immunotherapy resistance of liver cancer	Yijun Lu	Received

P-27	From Bulk to Single-cell RNA sequencing: A Prognostic Risk Score Reveals Tumor Microenvironment Heterogeneity in HBV-related Hepatocellular Carcinoma	Chenxing Zhao	Received

P-28	Study on the Role and Mechanism of SEPHS1 in Promoting the Malignant Progression of Hepatocellular Carcinoma	Shuting Zhou	Received

P-29	cfDNA-derived Tumour Fraction Predicts Clinical Outcomes in Patients with HCC Receiving Radiotherapy for Intrahepatic Oligoprogression on Immunotherapy	Landon Chan	Received

P-31	Hepatic decompensation Is driven by underlying liver disease rather than immunotherapy choice in inresectable hepatocellular carcinoma	Manon Allaire	Received

P-32	Stromal TGF-ß3 drives EMT and pro-metastatic reprogramming in intrahepatic cholangiocarcinoma and associates with treatment response	Merle Fischer	Received

P-33	Targeting Dickkopf-1 Unlocks Synergistic Antitumor Immunity with PD-L1 Blockade in Hepatocellular Carcinoma	Seung Up Kim	Received

P-34	Monoclonal Antibodies Targeting Extracellular Region of Cell Surface LANCL1 Suppresses Tumorigenesis in Hepatocellular Carcinoma	Yu Man Tsui	Received

P-35	LR-VID: A Long-Read Sequencing-Based Detector for Comprehensive and High-Resolution Characterization of Hepatitis B Virus Integrations in Hepatocellular Carcinoma	Hoi Ying Chan	Received

P-36	Targeting CRIP1 condensation supresses the development and the immune escape of hepatocellular carcinoma	SHU LIZHUANG	Received

P-37	Targeting Wnt/ß-Catenin with Lipophilic Statins Sensitizes Hepatocellular Carcinoma to Lenvatinib	Hyo Jin Nam	Received

P-38	Inter-individual variability in immune responses to PD-L1 blockade in HCC	Luca Grisetti	Received

P-40	The PRMT1–ROR1–DHCR7 axis dictates ferroptosis sensitivity in hepatocellular carcinoma	JUNJIE ZHOU	Received

P-41	Hepatitis B virus integration in primary and metastatic hepatocellular carcinoma: insights into clonal evolution and distant spread	Xueying Lyu	Received

P-42	Spatial organization of immune and vascular niches determines response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma	Julia Huguet	Received

P-43	Feasibility of Hyperpolarized [1-13C] Pyruvate MRI In Patients with Hepatocellular Carcinoma	Uffe Kjrgaard	Received

P-44	Predicting Atezolizumab-Bevacizumab Response in HCC: Head-to-Head Comparison of ALBI and CRAFITY Scoring Systems	Muhammad Uwais Ashraf	Received

P-45	trans-chalcone enhances cisplatin sensitivity by inducing GPX4-mediated ferroptosis in hepatoblastoma.	yamuna gurau	Received

P-46	Atezolizumab and bevacizumab therapy combined with expanded NK cells significantly prolongs survival in vivo hepatocellular carcinoma model.	SANGYOUN HWANG	Received

P-47	Early Detection and Prediction of Liver Metastases: The Role of Serum Biomarkers in Clinical Decision-Making	Ondrej Topolcan	Received

P-48	Ferula assafoetida Triggers Programmed Cell Death and Immunomodulates Pro-Survival Signaling in HepG2 Human Hepatocellular Carcinoma Cells	Asmaa Mostafa	Received

P-49	Effects of resistance training as a preventive strategy against hepatic cancer via modulation of hepatic cell proliferation in a Notch1 overexpression animal model	Ana Paula Azevedo Macedo	Received

P-50	Soluble FAP sustains cancer-associated fibroblast activation via a STAT3/IL-6 positive feedback loop in hepatocellular carcinoma	Pil Soo Sung	Received

P-51	Proton pump inhibitors use, gut microbiome composition and outcomes of patients with hepatocellular carcinoma treated with immunotherapy in first-line setting	Marco Sanduzzi Zamparelli	Received

P-52	Simplified BALAD Score as a Biomarker for First-Line Immune Checkpoint Inhibitor Selection in Unresectable Hepatocellular Carcinoma	Atsushi Hiraoka	Received

P-53	Unmasking the Burden of Liver Cancer in France: Nationwide Incidence, Prevalence and Mortality of HCC and iCCA from Real-World Data (2015–2021)	Vaele Zannou	Received

P-54	Neutrophil-to-Lymphocyte Ratio and Extrahepatic Spread Predict Response and Survival in Unresectable Hepatocellular Carcinoma	Sung Won Lee	Received

P-55	Genomic Profiles as Determinants of Therapeutic Efficacy in Hepatocellular Carcinoma: Towards Precision Medicine	Kwon Yong Tak	Received

P-57	Contraceptive Use in Relation to Gallbladder Cancer Risk: Findings from the Chile Biliary Longitudinal Study	Rime Jebai	Received

P-58	Three-Dimensional Margin Assessment Predicts Local Tumor Progression After Stereotactic Microwave Ablation of Small HCC =3 cm	Philippe Lauber	Received

P-59	Open hepatectomy VS. laparoscopic hepatectomy for patients with subcupsular hepatocellular carcinoma	Wei Peng	Received

P-60	Gender-Dimorphism Linked Distinct Gut Microbial Signature in Hepatocellular Carcinoma Patients.	Min Gi Cha	Received

P-61	CLINICALLY SIGNIFICANT PORTAL HYPERTENSION, RATHER THAN ALBI GRADE, IS THE MOST RELEVANT PROGNOSTIC FACTOR IN PATIENTS RECEIVING SYSTEMIC THERAPY FOR HEPATOCELLUAR CARCINOMA.	Federico Piñero	Received

P-63	MASLD and the Risk of Hepatocellular Carcinoma in Antiviral-Naïve Chronic Hepatitis B: Potentiating Effect of Alcohol Consumption in a Longitudinal Cohort	Aryoung Kim	Received

P-65	Non-cirrhotic HCC: MASLD-driven, late presentation, and worse overall survival compared with cirrhotic HCC	Saleh Alessy	Received

P-66	18F-FDGal uptake on PET/CT correlates with tumor differentiation and predicts mortality in patients with hepatocellular carcinoma	Michael Sørensen	Received

P-67	Clinical characterization of gallbladder cancer in a Mexican cohort: insights from a real-world database	Jaqueline Quevedo	Received

P-69	Risk Factors, Clinical Characteristics, and Outcomes of Cholangiocarcinoma in Egyptian Patients: A Multicentre Retrospective Study	Hend Shousha	Received

P-70	Refining Post-Transplant Recurrence Risk Stratification in Hepatocellular Carcinoma Using Machine Learning	xu yang	Received

P-71	Temporal, Regional, and Demographic Patterns of Abdominal Imaging in Hepatocellular Carcinoma patients in the United States: 2016 – 2024	Pareen Vora	Received

P-72	INFLUENCE OF DIFFERENT VARIABLES ON SERUM PIVKA-II CONCENTRATION IN A COHORT OF PATIENTS WITH ADVANCED CHRONIC LIVER DISEASE IN THE ABSENCE OF HEPATOCELLULAR CARCINOMA	María Varela Calvo	Received

P-73	A novel prognostic model integrating the ASAP score and neutrophil-to-lymphocyte ratio in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter cohort study	Jeayeon Park	Received

P-74	Prevalence and Clinical Correlates of Portal Vein Thrombosis in Hepatocellular Carcinoma	Saleh Alessy	Received

P-76	Hepatocellular carcinoma surgical resection changes plasmatic bacterial RNA signatures.	PALOMA SANGRO	Received

P-77	Diagnostic Performance of PIVKA-II in Comparison with AFP, CA 19-9, CA 72-4 and HE4 in Hepatocellular Carcinoma	Martina Pestova	Received

P-79	Methylation-based ctDNA monitoring for recurrence risk stratification in resected colorectal cancer liver metastases: interim analysis of the CLIMB study	Ruizhe Li	Received

P-80	Real-World Outcome of Atezolizumab Plus Bevacizumab in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma: A Study of 334 Patients	Mohamed Abdallah	Received

P-81	Model to Predict of Hepatic Decompensation during Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma	David Kaplan	Received

P-82	Body Surface Area–Adjusted Bevacizumab Exposure and Clinical Outcomes in Atezolizumab Plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma: A Nationwide Real-World Study	Kaho Aoe	Received

P-83	Tislelizumab plus donafenib combined with transarterial chemoembolization in patients with resected high-risk hepatocellular carcinoma (TIDE): updated results from a phase II trial	Wei Peng	Received

P-84	Meta-analysis comparing real-world effectiveness of lenvatinib vs other tyrosine kinase inhibitors in unresectable hepatocellular carcinoma after atezolizumab + bevacizumab.	Wilson Ngai	Received

P-85	Real-World Four-Year Outcomes of Atezolizumab–Bevacizumab in Hepatocellular Carcinoma: Results from the CHIEF French Cohort	Manon Allaire	Received

P-89	Differential toxicity profiles from first-line immunotherapy for unresectable hepatocellular carcinoma: a comparative analysis of atezolizumab plus bevacizumab versus durvalumab plus tremelimumab	Emanuela Di Giacomo	Received

P-91	Multicenter Propensity-Weighted Comparison of Hepatic Arterial Infusion Chemotherapy and Tyrosine Kinase Inhibitors in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Atezolizumab–Bevacizumab	Pil Soo Sung	Received

P-92	Beyond the Algorithm: Tumor-Board Determinants of Treatment-Stage Migration Across the BCLC stages (2020–2024)	Marta Fortuny	Received

P-93	REAL-WORLD OUTCOMES OF PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED WITH DURVALUMAB PLUS TREMELIMUMAB WHO MET OR DID NOT MEET THE INCLUSION CRITERIA FOR THE PHASE 3 HIMALAYA TRIAL	TOSHIFUMI TADA	Received

P-94	Patients with hepatocellular carcinoma should benefit from salvage transjugular intrahepatic portosystemic shunt when indicated	Manon Allaire	Received

P-95	Efficacy and safety of atezolizumab plus bevacizumab (Atezo/Bev) in patients with unresectable hepatocellular carcinoma (uHCC) and comorbidities: Post-hoc final analysis of the ATHECA study	Bruno Sangro	Received

P-96	Sequential Therapy Patterns and Prognostic Impact of First-Line Treatment Response in Unresectable Hepatocellular Carcinoma Patients with Failure of Atezolizumab plus Bevacizumab	Jiwon Yang	Received

P-97	Percutaneous Cryoablation for Hepatocellular Carcinoma in Anatomically Critical Locations: Clinical Outcomes and Safety	Sejin Choi	Received

P-98	Conversion surgery after immunotherapy in initially unresectable hepatocellular carcinoma: a French multicenter retrospective study	Shinha Kouadou	Received

P-99	Outcomes of Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma: Impact of Relative Bevacizumab Exposure	Emi Tanaka	Received

P-100	Transjugular intrahepatic portosystemic shunt as a bridging strategy to hepatocellular carcinoma treatment in patients with refractory ascites or hydrothorax	Manon Allaire	Received

P-102	Clinical Impact of a Comprehensive Respiratory Training Program in Stereotactic Body Radiation Therapy for Liver Tumors: Implications for Breath-Hold Eligibility, Margin Reduction, and Breathing Regularity	Sang Min Yoon	Received

P-103	Atezolizumab plus bevacizumab (Atezo/Bev) in patients with unresectable hepatocellular carcinoma (uHCC) treated in Spain according to macrovascular invasion (MVI): Post-hoc final analysis of the ATHECA study	María Reig	Received

P-104	Optimizing yttrium-90 radioembolization in hepatocellular carcinoma: efficacy, dosimetry, and response assessment using mRECIST and LI-RADS TRA.	Maria Varela	Received

P-105	Post-Progression Outcomes and Predictors of Survival in Advanced Hepatocellular Carcinoma Treated with First-Line Immune Checkpoint Inhibitors	Elisa Bocchero	Received

P-106	Younger age and clinical outcomes in patients with unresectable hepatocellular carcinoma (uHCC) treated with camrelizumab + rivoceranib vs sorafenib (CARES-310)	Arndt Vogel	Received

P-107	Real-life safety and efficacy of immunotherapy for advanced biliary tract carcinoma in a national multicentric cohort	Leonardo Da Fonseca	Received

P-108	Comparative Survival Outcomes of SBRT and TARE in Intermediate-Stage Hepatocellular Carcinoma: A Population-Based Study	Alisa Likhitsup	Received

P-109	Comparative Survival Outcomes of Stereotactic Body Radiation Therapy Versus Transarterial Radioembolization in Locally Advanced Hepatocellular Carcinoma: A SEER Research Plus Analysis, 2016–2023.	Alisa Likhitsup	Received

P-110	Supportive care needs, navigation interventions, and patient-reported wellbeing among patients with hepatobiliary cancers in a structured navigation programme in India	Priyanka Joshi	Received

P-111	Clinical Outcomes and Downstaging Potential of Immune Checkpoint Inhibitors in Large Hepatocellular Carcinoma: A Real-World Irish Experience	Hebatalla Ismail	Received

P-112	The role of modern radiotherapy techniques for the treatment of hepatocellular carcinoma: An updated systematic review and meta-analysis	SUN HYUN BAE	Received

P-113	BEVACIZUMAB IN ADVANCED HEPATOCELLULAR CARCINOMA OUTSIDE CLINICAL TRIALS: CONSENSUS RECOMMENDATIONS	Leonardo Da Fonseca	Received

P-114	Untreated HBV-infected advanced fibrosis, if HBV-DNA is detectable, has HCC risk comparable to antivirals-treated cirrhosis	Seung Up Kim	Received

P-119	Treatment Pathways and Outcomes of Multidisciplinary Management for Hepatocellular Carcinoma: A 5-Year Real-World Study From a High-Volume Center	Haifeng Liang	Received

P-120	Gemcitabine, Cisplatin and Durvalumab in Advanced Biliary Tract Cancer: Retrospective Single Centre Real-World Outcomes and Subsequent Treatment	Joycelyn Lee	Received

P-121	Prognostic value of baseline SIRI and ALBI grade in patients with advanced biliary tract cancer treated with chemo-immunotherapy	Rita Balsano	Received

P-123	Combination of radiotherapy and durvalumab/gemcitabine/cisplatin therapy improve survival in biliary tract cancer (especially extrahepatic bile duct cancer) patients	SANGYOUN HWANG	Received

P-125	Neoadjuvant therapy of sequential transcatheter arterial chemoembolization, camrelizumab and apatinib for single large hepatocellular carcinoma (NEO-START): updated results from a randomized controlled trial	Diao Kong	Received

P-126	ROSETTA HCC-206: A phase 1/2 trial of first-line pumitamig as monotherapy or combined with ipilimumab in advanced or unresectable hepatocellular carcinoma	David Riding	Received

P-127	PRODIGE 89 UCGI 44 ALICE (NCT06904170): An integrated Phase II/III randomized study comparing durvalumab and tremelimumab +/- Hepatic ArteriaL Infusion Chemotherapy with GEMOX in hepatocellular Carcinoma with high tumor burdEn	Julien Edeline	Received

P-132	ACAT1-mediated NPM1 acetylation orchestrates fatty acid metabolism reprograming and promotes immunotherapy resistance in hepatocellular carcinoma	Zhenbin Ding	Received

P-133	Balancing Tumor Control and Graft Safety in Pretransplant Immune Checkpoint Inhibition for Hepatocellular Carcinoma Beyond the Milan Criteria at Transplantation: A Single-Center Retrospective Cohort Study	Zhenbin Ding	Received

ILCA 2026 Annual Conference

3-5 September 2026, Brussels

Help Line

Homepage

Personal Area

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 03/09/2026 TO 03/09/2027

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions